Newborn bio business Mestag Therapeutics raises $11m seed cash

A new Cambridge UK BioMedTech business fighting inflammatory disease and cancer has launched with $11 million seed cash from healthcare backers SV Health Investors and Johnson & Johnson Innovation.

A high-class team of scientists at Mestag Therapeutics, based at Chesterford Research Park, is developing therapeutics targeting activated fibroblast populations across these disease areas.

Read the full story by Tony Quested in Business Weekly



Looking for something specific?